ImmuPharma Intangible Assets from 2010 to 2026

IMM Stock   8.03  0.30  3.60%   
ImmuPharma PLC's Intangible Assets are decreasing over the years with slightly volatile fluctuation. Intangible Assets are expected to dwindle to 8,398. Intangible Assets is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. View All Fundamentals
 
Intangible Assets  
First Reported
2006-03-31
Previous Quarter
K
Current Value
K
Quarterly Volatility
208 K
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check ImmuPharma PLC financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ImmuPharma PLC's main balance sheet or income statement drivers, such as Depreciation And Amortization of 75 K, Interest Expense of 2.2 K or Selling General Administrative of 1.5 M, as well as many indicators such as . ImmuPharma financial statements analysis is a perfect complement when working with ImmuPharma PLC Valuation or Volatility modules.
  
This module can also supplement various ImmuPharma PLC Technical models . Check out the analysis of ImmuPharma PLC Correlation against competitors.
Analyzing ImmuPharma PLC's Intangible Assets over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Intangible Assets has evolved provides context for assessing ImmuPharma PLC's current valuation and future prospects.

Latest ImmuPharma PLC's Intangible Assets Growth Pattern

Below is the plot of the Intangible Assets of ImmuPharma PLC over the last few years. It is non-physical assets possessed by a company, such as patents, trademarks, and copyrights, which provide long-term value. ImmuPharma PLC's Intangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ImmuPharma PLC's overall financial position and show how it may be relating to other accounts over time.
Intangible Assets10 Years Trend
Slightly volatile
   Intangible Assets   
       Timeline  

ImmuPharma Intangible Assets Regression Statistics

Arithmetic Mean447,601
Geometric Mean260,210
Coefficient Of Variation50.28
Mean Deviation154,797
Median483,039
Standard Deviation225,074
Sample Variance50.7B
Range756.6K
R-Value(0.86)
Mean Square Error13.9B
R-Squared0.74
Slope(38,410)
Total Sum of Squares810.5B

ImmuPharma Intangible Assets History

2026 8397.81
2025 8839.8
2024 9822.0
2023447.6 K
2022473.9 K
2021477.6 K
2020484 K

About ImmuPharma PLC Financial Statements

ImmuPharma PLC stakeholders use historical fundamental indicators, such as ImmuPharma PLC's Intangible Assets, to determine how well the company is positioned to perform in the future. Although ImmuPharma PLC investors may analyze each financial statement separately, they are all interrelated. For example, changes in ImmuPharma PLC's assets and liabilities are reflected in the revenues and expenses on ImmuPharma PLC's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in ImmuPharma PLC. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Intangible Assets8.8 K8.4 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in ImmuPharma Stock

ImmuPharma PLC financial ratios help investors to determine whether ImmuPharma Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in ImmuPharma with respect to the benefits of owning ImmuPharma PLC security.